糖尿病合并骨质疏松的临床治疗分析

Clinical Analysis of Diabetes Mellitus Complicated with Osteoporosis

目的研究糖尿病合并骨质疏松的临床治疗。方法以我院2017年8月至2018年8月收治的70例糖尿病合并骨质疏松患者作为本次研究活动的观察对象,以治疗用药不同进行分组,分为对照组(35例,单用阿仑膦酸钠治疗)与试验组(35例,加用阿托伐他汀),比较两组的疼痛情况、骨密度、临床疗效情况。结果两组治疗前以及治疗3个月的疼痛评分无明显差异(P> 0.05),试验组治疗6个月、12个月时的疼痛评分明显低于对照组(P <0.05);两组治疗前股骨粗隆、股骨颈、前臂、腰椎正位骨密度评分无显著差异(P> 0.05),治疗后试验组上述各项骨密度评分均高于对照组(P <0.05);试验组总有效率(91.43%)高于对照组(71.43%),P <0.05。结论为糖尿病合并骨质疏松患者进行阿仑膦酸钠以及阿托伐他汀联合治疗,能改善骨密度,缓解疼痛感,治疗效果明显。

Objective To study the clinical treatment of diabetes with osteoporosis.Methods Taking 70 patients with diabetes and osteoporosis admitted in our hospital from August 2017 to August 2018 as the observation objects of this research activity,based on the random number table method,a control group(35 cases,single use A Lendronate sodium treatment)and the experimental group(35 cases,plus atorvastatin),to compare the pain,bone density,and clinical efficacy of the two groups.Results There was no significant difference in the pain scores of the two groups before treatment and 3 months of treatment(P>0.05),the pain scores of the experimental group at 6 months and 12 months of treatment were significantly lower than those of the control group(P<0.05);there was no significant difference in the bone mineral density scores of the femoral trochanter,femoral neck,forearm,and lumbar spine before treatment between the two groups(P>0.05),after treatment,the the above-mentioned bone mineral density scores of the experimental group were higher than those of the control group(P<0.05);the total bone density scores of the experimental group The effective rate(91.43%)was higher than that of the control group(71.43%),P<0.05.Conclusion The combined treatment of alendronate and atorvastatin for diabetic patients with osteoporosis can improve bone density,relieve pain,and have obvious therapeutic effects.